Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer cell immunoglobulin-like receptors (KIRs) are a family of type I transmembrane glycoproteins primarily expressed on natural killer (NK) cells and some T lymphocytes. KIRs regulate NK cell activity by interacting with MHC class I molecules (HLA class I alleles) on target cells. They can be inhibitory or activating, allowing NK cells to distinguish between healthy self-cells and abnormal targets. KIR genes are highly polymorphic, contributing to diverse immune responses. KIRs play roles in immunity, tumor surveillance, autoimmunity, pregnancy, and transplantation.
Modulation of NK/T-cell activity via interaction with HLA class I molecules; inhibition or activation of cytotoxic responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Killer Cell Immunoglobulin-like Receptor (KIR).